Economic model of Ulipristal Acetate in the long term, intermittent treatment of uterine fibroids — a Canadian setting

Health economic evaluation compares the associated costs and the clinical outcomes of multiple treatment alternatives and is presently used by payers as one of the many types of evidence to inform which drugs to fund. Given existing health-care budgetary constraints, payers are increasingly interested in knowing whether a new health technology will provide value (i.e. […]

Read More